Mode
Home
Conditions Medications Drug Pipeline Weekly Digests Questions
Text Size
Log in / Sign up
Home › Medications › trastuzumab emtansine

trastuzumab emtansine

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Oncology Sys. Review
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Frontiers May 8, 2026
Trastuzumab emtansine and trastuzumab deruxtecan use in three patients with ERBB2-amplified rare tumors
Oncology Cohort
Trastuzumab emtansine and trastuzumab deruxtecan use in three patients with ERBB2-amplified rare tumors Rare tumors respond to targeted antibody drug treatments
This retrospective case series evaluated three patients with ERBB2-amplified rare tumors, including periampullary, salivary duct, and poorly…
Three patients with rare, aggressive cancers saw significant tumor shrinkage after receiving targeted antibody drug therapies.
Frontiers Apr 30, 2026